Scinai highlights new funding and cdmo growth ahead of bio international convention 2025

Ceo amir reichman to meet investors, pharma partners, and cdmo clients at global biotech conference jerusalem , june 12, 2025 /prnewswire/ -- scinai immunotherapeutics ltd. (nasdaq: scni), a biopharmaceutical company developing inflammation and immunology (i&i) therapies and offering biologics cdmo services through its scinai bioservices unit, today announced ceo amir reichman's participation in the bio international convention 2025 (june 16–19, boston).
CDMO Ratings Summary
CDMO Quant Ranking